[Bacteriological studies on cefatrizine (S-640 P) (author's transl)].
D000818:Animals; D002506:Cephalexin / Q000494:pharmacology; D002511:Cephalosporins / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D004926:Escherichia coli / Q000187:drug effects; D004927:Escherichia coli Infections / Q000188:drug therapy; D007709:Klebsiella / Q000187:drug effects; D007710:Klebsiella Infections / Q000188:drug therapy; D051379:Mice; D008826:Microbial Sensitivity Tests; D011485:Protein Binding; D011512:Proteus Infections / Q000188:drug therapy; D012475:Salmonella / Q000187:drug effects; D012760:Shigella / Q000187:drug effects; D013045:Species Specificity; D013203:Staphylococcal Infections / Q000188:drug therapy; D013290:Streptococcal Infections / Q000188:drug therapy; D013291:Streptococcus / Q000187:drug effects; D013296:Streptococcus pneumoniae / Q000187:drug effects; D013297:Streptococcus pyogenes / Q000187:drug effects; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use
D002511:Cephalosporins; D014230:Triazoles; D002506:Cephalexin